Omega-3 fatty acid supplementation Nutritional, Metabolic, Endocrine Omega-3 fatty acid supplementation
Conditions
Interventions
Patients are manually randomised to the order in which they will take the two supplements by the hospital research pharmacist. The two supplements are:
1. Omega-3 ethyl esters providin
Sponsors
BASF AS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy males and females 2. Age 50 to 70 years 3. Body mass index 20 to 35 kg/m2 5. Not eating more than one oily fish meal per week 6. Willing to adhere to the study protocol 7. Able to provide written informed consent 8. Omega-3 index (EPA+DHA in red blood cells) = 6.5 at screening visit
Exclusion criteria
Exclusion criteria: 1. Diabetic (type 1 or type 2) 2. Vegetarian or vegan and unwilling to consume capsules with a beef gelatine coating 3. Use of prescribed medicine to control inflammation 4. Smokers 5. Alcohol consumption > 14 units per week 5. Chronic gastrointestinal problems (e.g. IBD, IBS, celiac disease, cancer) 6. Allergic to fish 7. Use of fish oil or other oil supplement 8. Participation in another clinical trial (currently or in the 12 weeks prior to study entry) 9. Pregnancy or lactation 10. Blood donations during 3 months prior to or during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of EPA and DHA in plasma measured by gas chromatography at different time points up to 12 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability will be assessed simply by monitoring adverse events. Subjects will spend 2 x 12 hour days for clinic visits and adverse events will be monitored across each of these visits. | — |
Countries
England, United Kingdom
Outcome results
None listed